omeprazole + amoxicillin + metronidazole

This drug is a fixed-dose combination of three agents—omeprazole, amoxicillin, and metronidazole—used primarily for the eradication of Helicobacter pylori infection in patients with peptic ulcer disease. Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Metronidazole is a nitroimidazole antibiotic and antiprotozoal agent that disrupts DNA synthesis in susceptible organisms, particularly anaerobic bacteria such as H. pylori. The combination leverages synergistic effects to increase eradication rates of H. pylori and promote ulcer healing[1][3][5][8].

Other names

OAMOAM triple therapy